Investigators reviewed 116 pediatric diabetic ketoacidosis (DKA) episodes managed in a tertiary pediatric emergency department and intensive care unit between January 2022 and June 2025. They observed that hypophosphatemia developed in 72 episodes, representing 62.1% of the cohort. That prevalence signals phosphate decline is common during DKA treatment in children. The cohort showed measurable biochemical differences at presentation: affected patients had lower admission pH (7.03±0.13 vs. 7.12±0.17; P=0.002), lower bicarbonate (7.8±2.4 vs. 9.8±3.3 mEq/L; P<0.001), and lower potassium levels (4.43±0.96 vs. 4.81±0.66 mEq/L; P=0.024). Electrolyte disturbances clustered with low phosphate—hyponatremia and hypokalemia occurred more often, whereas hyperkalemia was less frequent in the hypophosphatemia group (all P<0.05). The study team recorded demographic and admission biochemical parameters and compared outcomes between groups.
The authors used multivariable logistic regression to identify independent predictors of hypophosphatemia. Two admission variables remained significant: lower admission pH and lower baseline phosphate concentration. Specifically, lower admission pH was associated with markedly higher odds of developing hypophosphatemia (reported OR: 0.008; 95% CI: 0.000–0.219; P=0.004), and lower baseline phosphate independently predicted subsequent hypophosphatemia (reported OR: 0.67; 95% CI: 0.47–0.97; P=0.031). The analysis therefore linked the severity of metabolic acidosis at presentation with the risk of falling phosphate during DKA management. The source did not report additional details about model covariates beyond those summarized in the abstract.
Data indicated a positive correlation between baseline phosphate and nadir phosphate during treatment (r=0.303; P<0.001). In practical terms, patients with higher phosphate at presentation tended to have higher lowest phosphate values during therapy. The authors interpreted this as evidence that initial phosphate status partially determines the depth of phosphate decline while receiving DKA treatment. The abstract did not provide granular time-course data, specific phosphate nadir timing, or protocolized replacement strategies; those methodological details were not reported in the source abstract.
Average hospitalization was longer in the hypophosphatemia group (85.3±75.2 vs. 56.2±36.4 hours; P=0.018). Despite that unadjusted difference, multivariable linear regression of log-transformed length-of-stay values found hypophosphatemia was not independently associated with hospitalization duration. Instead, higher admission pH independently predicted shorter hospital stays (β = -0.957; P=0.026). The investigators concluded that low phosphate appears to be a marker of more severe disease at presentation, rather than an independent driver of longer short-term hospitalization in this cohort. The abstract did not report other clinical endpoints such as neurological complications, respiratory failure, or need for organ support in relation to phosphate status.
This work was a retrospective analysis of 116 DKA episodes treated at a tertiary pediatric emergency department and intensive care unit between January 2022 and June 2025. Investigators recorded demographics, admission biochemical parameters, and clinical outcomes; hypophosphatemia was defined by age-specific reference ranges. The source abstract reports no conflicts of interest. The authors noted that determinants and clinical implications of hypophosphatemia in pediatric DKA are incompletely defined—a gap that motivated the study. The abstract did not provide further methodological specifics such as center-level protocols for phosphate monitoring or replacement, or whether the cohort represented a single center versus multiple centers beyond the stated tertiary emergency and intensive care setting. Those details were not reported in the abstract and therefore are not included here.
Limitations documented or implied by the source include the retrospective design and the cohort context (tertiary emergency and intensive care), which may affect generalizability to other settings. The study did not demonstrate an independent effect of hypophosphatemia on length of stay after adjustment, leaving unanswered whether phosphate disturbances influence other clinically meaningful outcomes, such as neurological events or longer-term recovery measures.
The study team observed that hypophosphatemia is common during pediatric DKA and closely linked to the severity of metabolic acidosis at presentation. Whether correcting phosphate alters outcomes beyond serving as a biochemical marker of severity remains an open clinical question noted by the authors and not resolved by the presented data.